Deal Watch: J&J Partners On Bispecific Antibody R&D With F-Star, Xencor
Executive Summary
Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.